What is your approach to assessing for ICANS in a pediatric oncology patient with R/R B-cell ALL following CAR-T?

How do you adjust based on age or developmental level?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?

What are your top takeaways in Hematologic Malignancies from ASH 2025?

Would you treat patient with early stage unfavorable classic Hodgkin lymphoma with 6 cycles instead of 4 cycles of Nivo-AVD to avoid mediastinal radiation in young female?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.